ES2320788T3 - Uso de l-acetilcarnitina para el tratamiento del sindrome fibromialgico. - Google Patents

Uso de l-acetilcarnitina para el tratamiento del sindrome fibromialgico. Download PDF

Info

Publication number
ES2320788T3
ES2320788T3 ES05807584T ES05807584T ES2320788T3 ES 2320788 T3 ES2320788 T3 ES 2320788T3 ES 05807584 T ES05807584 T ES 05807584T ES 05807584 T ES05807584 T ES 05807584T ES 2320788 T3 ES2320788 T3 ES 2320788T3
Authority
ES
Spain
Prior art keywords
acid
treatment
acetylcarnitine
syndrome
magnesium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05807584T
Other languages
English (en)
Spanish (es)
Inventor
Aleardo Koverech
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of ES2320788T3 publication Critical patent/ES2320788T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
ES05807584T 2004-12-13 2005-11-10 Uso de l-acetilcarnitina para el tratamiento del sindrome fibromialgico. Expired - Lifetime ES2320788T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000606A ITRM20040606A1 (it) 2004-12-13 2004-12-13 Uso della acetil l-carnitina per il trattamento della sindrome fibromialgica.
ITRM04A0606 2004-12-13

Publications (1)

Publication Number Publication Date
ES2320788T3 true ES2320788T3 (es) 2009-05-28

Family

ID=35708966

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05807584T Expired - Lifetime ES2320788T3 (es) 2004-12-13 2005-11-10 Uso de l-acetilcarnitina para el tratamiento del sindrome fibromialgico.

Country Status (16)

Country Link
US (1) US8013016B2 (enExample)
EP (1) EP1824472B1 (enExample)
JP (1) JP5057990B2 (enExample)
KR (1) KR101240182B1 (enExample)
AT (1) ATE419847T1 (enExample)
CA (1) CA2585560C (enExample)
CY (1) CY1110576T1 (enExample)
DE (1) DE602005012317D1 (enExample)
DK (1) DK1824472T3 (enExample)
ES (1) ES2320788T3 (enExample)
IT (1) ITRM20040606A1 (enExample)
MX (1) MX2007006954A (enExample)
PL (1) PL1824472T3 (enExample)
PT (1) PT1824472E (enExample)
SI (1) SI1824472T1 (enExample)
WO (1) WO2006063639A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2840363A1 (en) * 2011-06-24 2012-12-27 K-Pax Pharmaceuticals, Inc. Compositions comprising a central nervous system stimulant and select micronutrients useful in the treatment of chronic fatigue
ES2962933T3 (es) 2020-12-14 2024-03-21 Ims Gear Se & Co Kgaa Procedimiento para la corrección de una señal de medición dependiente del tiempo de una unidad de motor-engranaje, así como procedimiento para detectar desgaste y/o un deterioro de la misma mediante este procedimiento de corrección

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1150396B (it) * 1982-12-09 1986-12-10 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico di miopa tie e distrofie muscolari
EP0681839A3 (en) * 1994-05-12 1997-11-12 Hirohiko Kuratsune A pharmaceutical preparation comprising an acylcarnitine
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US5935949A (en) * 1998-03-20 1999-08-10 Trustees Of Dartmouth College Use of androgen therapy in fibromyalgia and chronic fatigue syndrome
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
ITRM20010293A1 (it) 2001-05-29 2002-11-29 Sigma Tau Ind Farmaceuti Uso della acetil-l-carnetina per la preparazione di un medicamento per la prevenzione del dolore.
KR101027570B1 (ko) * 2002-05-03 2011-04-06 이스라엘 인스티튜트 포 바이올로지컬 리서치 중추 및 말초 신경계 장애의 치료를 위한 방법 및 조성물, 및 그에 유용한 신규 화합물

Also Published As

Publication number Publication date
EP1824472B1 (en) 2009-01-07
ITRM20040606A1 (it) 2005-03-13
JP5057990B2 (ja) 2012-10-24
ATE419847T1 (de) 2009-01-15
US20090076146A1 (en) 2009-03-19
KR101240182B1 (ko) 2013-03-07
KR20070091317A (ko) 2007-09-10
CY1110576T1 (el) 2015-04-29
CA2585560C (en) 2013-01-08
PL1824472T3 (pl) 2009-05-29
SI1824472T1 (sl) 2009-04-30
MX2007006954A (es) 2007-08-02
EP1824472A1 (en) 2007-08-29
CA2585560A1 (en) 2006-06-22
WO2006063639A1 (en) 2006-06-22
DK1824472T3 (da) 2009-03-30
JP2008534433A (ja) 2008-08-28
PT1824472E (pt) 2009-03-31
DE602005012317D1 (de) 2009-02-26
US8013016B2 (en) 2011-09-06

Similar Documents

Publication Publication Date Title
PT2701693T (pt) Tapentadol para prevenção e tratamento de depressão e ansiedade
EP1827450A2 (en) Methods for reducing the side effects associated with mirtazapine treatment
Marbach Medically unexplained chronic orofacial pain: temporomandibular pain and dysfunction syndrome, orofacial phantom pain, burning mouth syndrome, and trigeminal neuralgia
Rollinson et al. Postanoxic action myoclonus (Lance-Adams syndrome) responding to valproate
KR102004021B1 (ko) 무감각 없이 통증 경감을 위한 조성물과 방법
PT793962E (pt) Medicamento contendo um derivado da carnitina para tratamento de arteriosclerose obliterans
JP2020055840A (ja) 麻痺を伴わない疼痛緩和のための組成物および方法
JP4276779B2 (ja) 注意欠損／活動亢進症の治療のためのアルカノイルカルニチン誘導体の使用
ES2320788T3 (es) Uso de l-acetilcarnitina para el tratamiento del sindrome fibromialgico.
TW202237107A (zh) 用於治療疼痛之酚系trpv1促效劑之前藥
EP3554489A1 (en) Treatment of moderate and severe gastroparesis
ES2322455T3 (es) Uso de carnitinas para la prevencion y/o tratamiento de trastornos producidos por la andropausia.
US20080161604A1 (en) Acetyl L-Carnitine For Preventing Painful Peripheral Diabetic Neuropathy
US8952059B2 (en) Acetyl L-carnitine for the preparation of a medicament for the prevention of painful peripheral neuropathy in patients with type 2 diabetes
US7776913B2 (en) Carnitines for treating or preventing disorders caused by andropause
JP5274071B2 (ja) 線維筋痛症治療剤
KR20090103656A (ko) 섬유근육통 치료제
JP5685362B2 (ja) 有痛性末梢糖尿病性神経障害の予防のためのアセチルｌ−カルニチン
ES2425045T3 (es) Acetil-L-carnitina para la prevención de la neuropatía diabética periférica dolorosa
Jansen Common pain syndromes in older adults
EA021912B1 (ru) Способ профилактики и/или терапевтического лечения фибромиалгии